{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:03:02Z","timestamp":1792292582067,"version":"4.4.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ijantimicag.2020.106263","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T02:11:29Z","timestamp":1607998289000},"page":"106263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A.","family":"Cornely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Thomas M.","family":"File","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0660-5209","authenticated-orcid":false,"given":"Lynne","family":"Garrity-Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5682-9200","authenticated-orcid":false,"given":"Surya","family":"Chitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5906-2818","authenticated-orcid":false,"given":"Paul C.","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106263_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143276","article-title":"Rising United States hospital admissions for acute bacterial skin and skin structure infections: recent trends and economic impact","volume":"10","author":"Kaye","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2020.106263_bib0002","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/ndt\/gfq798","article-title":"Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease","volume":"26","author":"Viasus","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijantimicag.2020.106263_bib0003","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.ackd.2010.05.007","article-title":"Antibiotic pharmacokinetic and pharmacodynamic considerations in patients with kidney disease","volume":"17","author":"Eyler","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ijantimicag.2020.106263_bib0004","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/phar.2184","article-title":"Suboptimal clinical response rates with newer antibiotics among patients with moderate renal impairment: review of the literature and potential pharmacokinetic and pharmacodynamic considerations for observed findings","volume":"38","author":"Bidell","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2020.106263_bib0005","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1345\/aph.1G742","article-title":"Drug dosage adjustments according to renal function at hospital discharge","volume":"40","author":"van Dijk","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2020.106263_bib0006","first-page":"1487","article-title":"Drug dosing adjustments in patients with chronic kidney disease","volume":"75","author":"Munar","year":"2007","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.ijantimicag.2020.106263_bib0007","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1046\/j.1525-1497.2001.016006369.x","article-title":"Drug dosage in patients with renal failure optimized by immediate concurrent feedback","volume":"16","author":"Falconnier","year":"2001","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.ijantimicag.2020.106263_bib0008","first-page":"497","article-title":"Inappropriate drug dosage adjustments in patients with renal impairment","volume":"22","author":"Markota","year":"2009","journal-title":"J Nephrol"},{"key":"10.1016\/j.ijantimicag.2020.106263_bib0009","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/00498254.2016.1213465","article-title":"Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline","volume":"47","author":"Flarakos","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ijantimicag.2020.106263_bib0010","doi-asserted-by":"crossref","first-page":"e02057","DOI":"10.1128\/AAC.02057-17","article-title":"Pharmacokinetics and safety of omadacycline in subjects with impaired renal function","volume":"62","author":"Berg","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106263_bib0011","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.106263_bib0012","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"O'Riordan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.106263_bib0013","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","article-title":"Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial","volume":"19","author":"O'Riordan","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106263_bib0014","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1128\/AAC.00948-12","article-title":"A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections","volume":"56","author":"Noel","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106263_bib0015","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1128\/AAC.01393-16","article-title":"Randomized, open-label study of the pharmacokinetics and safety of oral and intravenous administration of omadacycline to healthy subjects","volume":"60","author":"Sun","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106263_bib0016","doi-asserted-by":"crossref","first-page":"e01487","DOI":"10.1128\/AAC.01487-17","article-title":"Safety and pharmacokinetics of the aminomethylcycline antibiotic omadacycline administered to healthy subjects in oral multiple-dose regimens","volume":"62","author":"Bundrant","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106263_bib0017","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02083-18","article-title":"Pharmacokinetics, safety, and clinical outcomes of omadacycline in women with cystitis: results from a Phase 1b study","volume":"63","author":"Overcash","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:38:24Z","timestamp":1760377104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920304830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0924857920304830"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106263","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106263"}}